Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 11/20 | 0.48 |
| ▸ | ACHE | P22303 | 5/20 | 0.43 |
| ▸ | BCHE | P06276 | 4/20 | 0.43 |
| ▸ | MPO | P05164 | 1/20 | 0.42 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.42 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22607141 | 0.94 | SOS1 (0.51) | SOS1ACHEBCHEGAAALOX12 | |
| SCHEMBL22607144 | 0.90 | SOS1 (0.53) | SOS1ACHEBCHE | |
| SCHEMBL22606643 | 0.89 | SOS1 (0.48) | SOS1ACHEBCHEMPO | |
| SCHEMBL22606795 | 0.89 | SOS1 (0.48) | SOS1ACHEBCHEGAAALOX12 | |
| SCHEMBL22607143 | 0.89 | SOS1 (0.52) | SOS1ACHEBCHEMPOERCC1 | |
| SCHEMBL22606967 | 0.89 | SOS1 (0.46) | SOS1ACHEBCHEMPOERCC1 | |
| SCHEMBL22606642 | 0.88 | SOS1 (0.47) | SOS1ACHEBCHEMPOERCC1 | |
| SCHEMBL22607055 | 0.87 | MPO (0.46) | SOS1ACHEMPO | |
| SCHEMBL22606966 | 0.84 | BCHE (0.52) | SOS1ACHEBCHEERCC1ERCC4 | |
| SCHEMBL22607014 | 0.81 | SOS1 (0.52) | SOS1ACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339537-A1 | NOVEL COMPOUND AS INHIBITOR AGAINST BINDING OF PF34 PROTEIN TO NEDD4-1 PROTEIN AND USE THEREOF | ENHANCEDBIO, INC. (KR) | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339537-A1 | NOVEL COMPOUND AS INHIBITOR AGAINST BINDING OF PF34 PROTEIN TO NEDD4-1 PROTEIN AND USE THEREOF | NEDD4, PFDN1, PF4 | SOS1 1806/4885ACHE 3500/4885BCHE 4287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.